Morphea often follows relapsing-remitting course
And MRI can be useful to track deep disease, researchers say
Morphea, or localised scleroderma, often follows a relapsing-remitting course over several years, but existing therapies appear to improve disease activity and stabilise damage, researchers report.
In two reports in JAMA Dermatology, US researchers investigated the disease course in patients with morphea treated with standard-of-care therapy and compared clinical assessment of deep morphea with MRI findings.
